Glenmede Trust’s Voyager Therapeutics VYGR Stock Holding History

Glenmede Trust’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-177	Closed	-$1K	–	2249
2020 Q3	$1K	Buy	+177	New	+$2.08K	﹤0.01%	2402

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Glenmede Trust's VYGR Position: Q4 2020 in Review

Glenmede Trust sold out of Voyager Therapeutics (VYGR) in Q4 2020, closing a stake of 177 shares — an estimated $1K sold.

Glenmede Trust first reported a position in VYGR in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 101 funds tracked by Wall St. Rank hold VYGR as of Q4 2020.

Glenmede Trust reported no remaining Voyager Therapeutics position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 177 Voyager Therapeutics shares in Q4 2020, an estimated $1K.
Glenmede Trust first reported a position in Voyager Therapeutics in Q3 2020 and held it in 1 quarter.
Glenmede Trust's Voyager Therapeutics position peaked at $1K in Q3 2020.
101 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.